Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioLineRx Ltd. (BLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8700+0.0200 (+0.70%)
At close: 4:00PM EDT
2.8800 +0.01 (+0.35%)
After hours: 05:56PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.8500
Open2.8700
Bid2.8200 x 900
Ask2.8800 x 800
Day's Range2.8100 - 2.8900
52 Week Range1.4500 - 6.3400
Volume257,222
Avg. Volume410,858
Market Cap132.568M
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-1.4400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
  • PR Newswire

    BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Globa

  • Insider Monkey

    11 Best Stocks for Long Term Growth

    In this article, we discuss the 11 best stocks for long-term growth. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks for Long Term Growth. As the economy recovers post COVID-19, many investors see the surge in consumer spending and the expansion of the digital economy […]

  • PR Newswire

    BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.

Advertisement
Advertisement